The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
Urol Oncol. 2019 Oct 29;:
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC).
Can Urol Assoc J. 2019 Oct;13(10):307-314
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108.
Cancer. 2019 Oct 03;:
Management of urachal cancer: A review by the Canadian Urological Association and Genitourinary Medical Oncologists of Canada.
Can Urol Assoc J. 2019 Jul 23;:
2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC).
Can Urol Assoc J. 2019 Jun 25;:
Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database.
Eur Urol Oncol. 2019 Jul 12;:
Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect.
Eur Urol. 2019 Jul 11;:
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials.
Eur Urol Oncol. 2019 May;2(3):248-256
Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer.
Oncotarget. 2019 Apr 26;10(31):2947-2958